Magnesium chloride, zinc oxide
Sold as Ultimag
Every registration of this product has been cancelled.
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
Background
Registration
- Applicants
- 1
- Registrations
- 1
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Cipla Medpro (Pty) LtdCancelled | Ultimag | tablets | X0079 | Not determined | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Ultimag tablets EACH TABLET CONTAINS MAGNESIUM CHLORIDE 660,0 mg ZINC OXIDE 6,0 mg | Tablets | X0079X/24/0079 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S1: Magnesium
- in oral preparations or mixtures containing more than 250 mg of Magnesium per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S0)
Consolidated Schedules 06 July 2026, lines 815 to 816
2 of 2 approved products with this ingredient carry S4 on their leaflet.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.